Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives Average Recommendation of “Moderate Buy” from Analysts

by · The Cerbat Gem

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the eight analysts that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $20.44.

MRNS has been the subject of several analyst reports. StockNews.com raised shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, January 27th. Truist Financial cut their price target on shares of Marinus Pharmaceuticals from $32.00 to $25.00 and set a “buy” rating for the company in a report on Wednesday, November 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $27.00 price target on shares of Marinus Pharmaceuticals in a report on Tuesday, December 5th.

Read Our Latest Stock Analysis on MRNS

Institutional Trading of Marinus Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. Nuveen Asset Management LLC lifted its holdings in shares of Marinus Pharmaceuticals by 1.1% during the 4th quarter. Nuveen Asset Management LLC now owns 139,752 shares of the biopharmaceutical company’s stock worth $1,519,000 after acquiring an additional 1,475 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Marinus Pharmaceuticals by 2.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,047 shares of the biopharmaceutical company’s stock worth $889,000 after acquiring an additional 2,281 shares during the last quarter. Metropolitan Life Insurance Co NY bought a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter worth $30,000. Deutsche Bank AG lifted its holdings in shares of Marinus Pharmaceuticals by 14.7% during the 3rd quarter. Deutsche Bank AG now owns 25,961 shares of the biopharmaceutical company’s stock worth $209,000 after acquiring an additional 3,321 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Marinus Pharmaceuticals by 94.4% during the 3rd quarter. Tower Research Capital LLC TRC now owns 7,541 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 3,661 shares during the last quarter. 88.26% of the stock is owned by institutional investors.

Marinus Pharmaceuticals Stock Up 1.6 %

MRNS opened at $9.77 on Friday. The company has a 50 day moving average of $10.09 and a 200 day moving average of $8.12. The company has a market cap of $533.15 million, a PE ratio of -3.69 and a beta of 0.95. Marinus Pharmaceuticals has a 12 month low of $5.57 and a 12 month high of $11.26. The company has a current ratio of 6.38, a quick ratio of 6.29 and a debt-to-equity ratio of 1.79.

About Marinus Pharmaceuticals

(Get Free Report

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

Recommended Stories